Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).
Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS. Wehmeier PM, et al. Among authors: schacht a. Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11. doi: 10.1186/1753-2000-2-11. Child Adolesc Psychiatry Ment Health. 2008. PMID: 18507848 Free PMC article.
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G. Wehmeier PM, et al. Among authors: schacht a. J Child Adolesc Psychopharmacol. 2007 Dec;17(6):813-30. doi: 10.1089/cap.2007.0025. J Child Adolesc Psychopharmacol. 2007. PMID: 18315453 Clinical Trial.
Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day.
Wehmeier PM, Schacht A, Dittmann RW, Döpfner M. Wehmeier PM, et al. Among authors: schacht a. Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):10. doi: 10.1186/1753-2000-2-10. Child Adolesc Psychiatry Ment Health. 2008. PMID: 18507847 Free PMC article.
Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies.
Wehmeier PM, Dittmann RW, Schacht A, Helsberg K, Lehmkuhl G. Wehmeier PM, et al. Among authors: schacht a. Child Adolesc Psychiatry Ment Health. 2009 Feb 9;3(1):5. doi: 10.1186/1753-2000-3-5. Child Adolesc Psychiatry Ment Health. 2009. PMID: 19203355 Free PMC article.
Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials.
Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V. Wehmeier PM, et al. Among authors: schacht a. Child Adolesc Psychiatry Ment Health. 2010 Dec 6;4:30. doi: 10.1186/1753-2000-4-30. Child Adolesc Psychiatry Ment Health. 2010. PMID: 21134277 Free PMC article.
Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device.
Wehmeier PM, Schacht A, Wolff C, Otto WR, Dittmann RW, Banaschewski T. Wehmeier PM, et al. Among authors: schacht a. J Child Adolesc Psychopharmacol. 2011 Oct;21(5):433-44. doi: 10.1089/cap.2010.0142. J Child Adolesc Psychopharmacol. 2011. PMID: 22040189 Clinical Trial.
235 results